ArticleMethods in molecular biology (Clifton, N.J.)2026
Tissue Pharmacokinetics of Antisense Oligonucleotides.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetics (PK) of antisense oligonucleotides (ASOs) is characterized by rapid distribution from plasma to tissue and by slow terminal plasma elimination, driven by redistribution from tissues. A quantitative understanding of tissue PK and target engagement, as demonstrated by RNA knockdown, is critical for successful drug discovery. This chapter describes and discusses appropriate experimental designs to characterize both the temporal and spatial PK aspects of ASOs. Key considerations, such as the choice of administration route, dosing regimen, single versus repeated dosing, and sampling points are addressed. The chapter also examines mathematical models of varying complexity, from empirical models to physiologically-based pharmacokinetic (PBPK) models, that support the understanding of ASO PK and guide clinical development.
Indexed as
Identifiers
42814311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.